// App-Quantinova.ai

3144 : Clofarabine, Melphalan, and Thiotepa, Followed by Allogeneic Unmodified Bone Marrow or Peripheral Blood Stem Cell Transplant, by Unmodified Double Cord Blood Transplant, or by CD34+ T-Cell Depleted Stem Cell Transplant for the Treatment of Hematologic Malignancies.

Researchers

Presenter

  • Guenther Koehne

Principal Investigators

  • Nancy A. Kernan

  • Rachel Kobos

  • Ann A. Jakubowski

  • Doris Ponce

  • Juliet Barker

  • James W. Young

  • Craig S. Sauter

  • Sergio Giralt

  • Richard J. O'Reilly

  • Susan E. Prockop

  • Trudy N. Small

  • Andromachi Scaradavou

  • Miguel-Angel Perales

  • Hugo R Castro-Malaspina

  • Esperanza B. Papadopoulos

  • Jenna D Goldberg

  • Elizabeth G Klein

Medical Centers

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Acute lymphoblastic leukemia

  • Acute myelocytic leukemia

  • Graft-versus-host disease

  • Hematological malignancies

  • Alpha-thalassemia myelodysplasia syndrome

  • Anemia

  • Sepsis

Biomarkers

  • Breakpoint Cluster Region

  • Cluster of Differentiation 34

  • Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein Epsilon

Drug/Treatment

  • Mycophenolate mofetil

  • CKD-4101

  • Methotrexate

  • Clofarabine

  • Tacrolimus

  • Melphalan

  • Thiotepa

  • thiocoraline

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved